Lineage Cell Therapeutics

A clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

[Lineage Cell Therapeutics @LineageCell]

All of us at $LCTX and CCN wish to express our gratitude to those who inspire us as #WeWorktoRestore - function, dignity, strength, clarity, independence, and hope.

@CEO_Culley #CellTherapy #ReplaceAndRestore #Careers

[Lineage Cell Therapeutics @LineageCell]

We appreciate Dr. Joe Pantginis of @HCWCO for hosting a fireside chat with $LCTX ‘s @CEO_Culley as part of @HCWCO 4th Annual BioConnect Investor Conference at @NasdaqExchange.

Replay available here: https://t.co/m6UMmQas5j

#CellTherapy #InvestorRelations #ReplaceandRestore

[Lineage Cell Therapeutics @LineageCell]

We’d like to thank European Pharmaceutical Review for featuring $LCTX ’s @CEO_Culley in its 2026 Cell and Gene Therapy report, where he discusses scalable, off-the-shelf cell therapies and the role of manufacturing, scale, and control in development.

Read the full report: https://t.co/H8zs4AoYug

#CellTherapy #RegenerativeMedicine #CellManufacturing

[Lineage Cell Therapeutics @LineageCell]

$LCTX reported first quarter 2026 financial results and will host a conference call at 4:30 pm ET / 1:30 pm PT today to provide a business update.

Learn more: https://t.co/Wb3S6EBykZ

#ReplaceAndRestore

[Lineage Cell Therapeutics @LineageCell]

$LCTX will report Q1 2026 financial and operating results on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT to provide a business update.

For more: https://t.co/tvEsKzdpar

#ReplaceAndRestore

[Lineage Cell Therapeutics @LineageCell]

OpRegen® (RG6501) 3-year Phase 1/2a clinical study results in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) were presented at @FightBlindness’ Retinal Therapeutics Innovation Summit 2026 on behalf of @Roche and @Genentech.

Imaging evidence of structural benefit and greater gains in visual acuity seen in study eyes in Cohort 4 patients (less advanced GA) at month 12, continuing through month 36. Differences as compared with fellow eyes increased over time, suggesting possible modification of the course of disease.

For more: https://t.co/cVSQszB4OF

$LCTX #CellTherapy #GeographicAtrophy #AMD #Retina

[Lineage Cell Therapeutics @LineageCell]

$LCTX @CEO_Culley joined @irat1onal on @ProgressPotent1 to discuss Lineage’s approach to allogeneic cell therapy, our proprietary AlloSCOPE™ manufacturing platform, and off-the-shelf cell therapies. https://t.co/BkUFpOV4kQ

#CellTherapy #RegenerativeMedicine #CellManufacturing #ReplaceAndRestore

[Lineage Cell Therapeutics @LineageCell]

Please join us in welcoming Priyantha Herath, M.D., Ph.D., to $LCTX as Senior Vice President, Head of Clinical.

A board-certified neurologist, Dr. Herath brings translational, regulatory and Phase 3 clinical development experience, with prior roles at @argenxglobal, @Alnylam, @VoyagerTx, and @JazzPharma. He received his M.D. with honors from University of Peradeniya and his Ph.D. in Neuroscience from Karolinska Institutet.

For more: https://t.co/vU44qN5XBx

#ReplaceandRestore #BiotechLeadership #ClinicalDevelopment #LeadershipTeam

[Lineage Cell Therapeutics @LineageCell]

$LCTX establishes a Scientific Advisory Board, with Joachim Fruebis, Ph.D., as its founding member.

He brings deep R&D and leadership experience across multiple therapeutic areas, most recently serving as Corporate VP, Cell Therapy R&D at @novonordisk. He received his Ph.D. and M.S. in Biology from the University Kaiserslautern, Germany, with research conducted at @UCSanDiego.

For more: https://t.co/vU44qN5XBx

#Biotech #CellTherapy #Leadership #ReplaceandRestore

[Lineage Cell Therapeutics @LineageCell]

$LCTX thanks @SDJournal for highlighting our expansion into corneal endothelial disease with COR1, targeting a growing global population affected by FECD.

Read the full article: https://t.co/hkfUuYhwLZ

#CellTherapy #Ophthalmology #Biotech #RegenerativeMedicine

[Lineage Cell Therapeutics @LineageCell]

$LCTX @CEO_Culley shares his perspective in @BioSpace on the growing complexity of drug discovery, highlighting the role of scalable platforms and aligning innovation with real-world clinical needs.

https://t.co/iiyz9pS40t

#DrugDiscovery #CellTherapy #Biotech #Innovation #RegenerativeMedicine

[Lineage Cell Therapeutics @LineageCell]

$LCTX has launched COR1, a corneal endothelial cell therapy program in preclinical development for corneal endothelial disease. Built on its AlloSCOPE™ platform, COR1 aims to deliver off-the-shelf CEnCs for Fuchs Endothelial Corneal Dystrophy (FECD) and Bullous Keratopathy.

For more: https://t.co/zOU1LKhCog

#CornealEndothelialDisease #Ophthalmology #FECD #CellTherapy

[Lineage Cell Therapeutics @LineageCell]

$LCTX

[Brian Culley @CEO_Culley]

Stopped for a pic at the Fischli and Weiss “Rock on top of Another Rock”, which evokes the beauty of pushing limits. An inspirational idea applicable to our regenerative medicine mission. Thanks for hosting us in Basel, Roche! $LCTX

[Lineage Cell Therapeutics @LineageCell]

$LCTX reported fourth quarter and full year 2025 financial results and will host a conference call at 4:30 pm ET / 1:30 pm PT today to provide a business update.

Learn more: https://t.co/HBTnnlNBOo

#ReplaceAndRestore

[Lineage Cell Therapeutics @LineageCell]

$LCTX will report 4Q and full year 2025 financial results on Thursday, March 5, 2026, and host a conference call at 4:30 pm ET / 1:30 pm PT to provide a business update.

Learn more: https://t.co/I6MMK84XVu

#ReplaceAndRestore

[Lineage Cell Therapeutics @LineageCell]

$LCTX has activated a second DOSED clinical study site for #OPC1, its allogeneic cell transplant therapy candidate for spinal cord injury, at @RanchoResearchI, in conjunction with their affiliated hospital, @RanchoRehab, where Charles Liu, M.D., Ph.D., will serve as Principal Investigator.

For more about Rancho Research Institute, please visit: https://t.co/Puegb6ieTp

For more about Rancho Los Amigos National Rehabilitation Center, please visit: https://t.co/CjQIzjAjRe

For more about DOSED, please visit: https://t.co/KI18YW8oAi

#ReplaceandRestore #ClinicalTrials #SCI #SpinalCordInjury

[Lineage Cell Therapeutics @LineageCell]

.@CEO_Culley of $LCTX spoke with @pharmaphorum reporter @JonahComstock about why allogeneic, off-the-shelf cell therapy still has a path beyond oncology, plus long-term tolerability data and what Lineage plans to share about its cell programs in 2026.

For more: https://t.co/wjHX44UYun

#CellTherapy #RegenerativeMedicine #Biotech

[Lineage Cell Therapeutics @LineageCell]

$LCTX

#OpRegen #dryAMD

[Brian Culley @CEO_Culley]

Genuinely thrilled to have another prominent retina specialist getting involved with the OpRegen program! A big $LCTX welcome to @ArshadKhanani Director of Clinical Research at Sierra Eye Associates and his outstanding team! Up to 16 clinical sites now.

[Lineage Cell Therapeutics @LineageCell]

Rami Skaliter, CEO of Cell Cure Neurosciences, a $LCTX subsidiary, is presenting at @HansonWade’s 4th Annual Ophthalmic Drug Delivery Summit in San Francisco, hosting a workshop session on overcoming clinical applicability challenges in cell therapy for vision and beyond.

For more about the conference: https://t.co/tlxtu6gQPl

#Ophthalmology #DrugDelivery #CellTherapy

[Lineage Cell Therapeutics @LineageCell]

.@CEO_Culley of $LCTX joined @Fraiser_K, the host of The Top Line podcast from @FiercePharma, for a conversation about investor sentiment and why manufacturing planning needs to start earlier than most teams think.

Listen here: https://t.co/51VzD7KOk4

#Biotech #CellTherapy #Manufacturing #HealthcareInnovation

[Lineage Cell Therapeutics @LineageCell]

.@CEO_Culley and the $LCTX business development team are in San Francisco for JPMorgan Healthcare Conference Week, where we’re looking forward to key investor, partnering, and biotech discussions.

#ReplaceAndRestore #RegenerativeMedicine #JPM2026